Research programme: Alzheimer's disease antibody therapeutics - Alector
Latest Information Update: 08 Nov 2013
At a glance
- Originator Alector
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 31 Oct 2013 Early research in Alzheimer's disease in USA (Parenteral)